Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

At Vertex, I’ve known Duncan 30 years ... we have VX-993 and we have other 1.8 inhibitors and we’re working on we’ve cracked NaV1.7 and are nearing the clinic. But that also means how ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

led by povetacicept and AbbVie-partnered dual CD28 and ICOS inhibitor acazicolcept, which is in a phase 2 lupus trial, with results due later this year. Vertex has built its business on genetic ...

Vertex Pharma's non-opioid painkiller suzetrigine ... The company emphasised that the NaV1.8 inhibitor met the primary endpoint with a statistically significant and "clinically meaningful" 2. ...

Pediatric AGA prevalence may be higher than previously described and over 8% of patients with pediatric AGA had disease onset prior to puberty.

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Google Cloud today announced new generative AI (gen AI) capabilities in Vertex AI Search for healthcare, including a new feature called Visual Q&A that searches tables, charts, and diagrams, and the ...

Here's why four Motley Fool contributors think chip giants Nvidia (NASDAQ: NVDA) and Micron Technologies (NASDAQ: MU), travel services company Airbnb (NASDAQ: ABNB), biotech behemoth Vertex ...